Blood test could replace brain surgery for tumor tracking
NCT ID NCT05925218
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to develop a liquid biopsy—a blood test—to detect tumor DNA in patients with high-grade gliomas, an aggressive type of brain cancer. Researchers will collect blood samples from 70 patients before and after standard radiotherapy to see if they can measure tumor changes without surgery. The goal is to create a non-invasive way to monitor how the tumor responds to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to monitor brain tumors, reducing the need for invasive biopsies.
- What could go wrong
- This is an early feasibility study with only 70 participants, so the test may not be sensitive enough or may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network
Toronto, Ontario, L4W4C2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Could an antiparasitic drug boost radiation against childhood brain tumors?
- Can a simple dye help surgeons see brain tumors in real time?